Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jan;21(1):8.
doi: 10.1038/s41569-023-00955-2.

Patisiran is beneficial for the treatment of TTR cardiac amyloidosis

Irene Fernández-Ruiz  1
Affiliations
Comment

Patisiran is beneficial for the treatment of TTR cardiac amyloidosis

Irene Fernández-Ruiz. Nat Rev Cardiol. 2024 Jan.
No abstract available

PubMed Disclaimer

Comment on

  • Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis.
    Maurer MS, Kale P, Fontana M, Berk JL, Grogan M, Gustafsson F, Hung RR, Gottlieb RL, Damy T, González-Duarte A, Sarswat N, Sekijima Y, Tahara N, Taylor MS, Kubanek M, Donal E, Palecek T, Tsujita K, Tang WHW, Yu WC, Obici L, Simões M, Fernandes F, Poulsen SH, Diemberger I, Perfetto F, Solomon SD, Di Carli M, Badri P, White MT, Chen J, Yureneva E, Sweetser MT, Jay PY, Garg PP, Vest J, Gillmore JD; APOLLO-B Trial Investigators. Maurer MS, et al. N Engl J Med. 2023 Oct 26;389(17):1553-1565. doi: 10.1056/NEJMoa2300757. N Engl J Med. 2023. PMID: 37888916 Free PMC article. Clinical Trial.

References

Original article
    1. Maurer, M. S. et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N. Engl. J. Med. 389, 1553–1565 (2023) - DOI - PubMed
Related article
    1. Aimo, A. et al. RNA-targeting and gene editing therapies for transthyretin amyloidosis. Nat. Rev. Cardiol. 19, 655–667 (2022) - DOI - PubMed